nect Biopharma (US:CNTB) Globenewswire·2025-05-20 13:00Core Insights - Connect Biopharma's rademikibart shows significant improvement in airway function (FEV1) within 24 hours and reduces acute exacerbations in asthma and COPD patients, supporting ongoing Phase 2 studies expected to report data in 1H26 [1][2] - Rademikibart demonstrates differentiated structural and molecular dynamics with enhanced IL-4Rα inhibition compared to dupilumab, providing a basis for its superior efficacy and safety profile [1][8] Group 1: Clinical Data - Rademikibart rapidly improves lung function (FEV1) during the first week of treatment, with most improvement observed within 24 hours [3] - Patients with elevated eosinophil counts (≥300 cells/µL) showed the greatest improvements in lung function and significant reduction in acute exacerbations [3] - In a post-hoc analysis, rademikibart significantly improved prebronchodilator FEV1 over 24 weeks, particularly in patients with eosinophilic-driven COPD [3] Group 2: Safety and Efficacy - Rademikibart treatment groups had lower proportions of patients with high post-baseline eosinophil counts compared to dupilumab, indicating a differentiated safety profile [8] - Mean eosinophil counts decreased by approximately 30% at Week 24 for rademikibart, while dupilumab treatment groups experienced increases between 50% and 120% [8] - Structural analysis revealed rademikibart's optimized binding to IL-4Rα, enhancing its efficacy compared to dupilumab [8] Group 3: Company Overview - Connect Biopharma is focused on transforming care for asthma and COPD, with rademikibart positioned as a potentially best-in-class anti-IL-4Rα antibody [5] - The company targets a significant unmet need in acute exacerbations, with approximately 1 million asthma and 1.3 million COPD patients in the U.S. experiencing such events annually [5] - Rademikibart has shown strong efficacy and safety data in Phase 2 trials, with rapid improvements in FEV1 observed within one week [5]